Loading…
Loading…
we were sort of surprised to see that one selected for the Medicare price reductions in 2028
curious your thoughts around updating the Street on sort of your longer-term outlook for Skyrizi and Rinvoq
Wondering if you can just sort of talk about the commercial opportunity for that indication
I thought products like your breast implants and Juvederm may be included right now. So curious if that's the case or not
comment a little more on pricing dynamics that you're seeing there as to how you've factored in pricing both for this year
give a sense of where you think the share is now for Botox and Juvéderm sort of this point in time
Just want any initial feedback you can share with us in terms of the initial launch and what doctors and patients are saying
what initial feedback is from doctors and is this buy and bill model?
your general level of enthusiasm
There's three products that are not on there anymore that were there. At the end of twenty twenty-three
I'm curious how you think about that product sort of in 2026 and beyond, both in the U.S.
has your ex U.S. sort of strategy at all evolved given sort of the threat of most-favored-nation pricing
comment on the sort of environment for business development now given all the macro volatility
Just curious if it's changed in any way your expectations for Cadence. I think that's maybe underappreciated
Can you just elaborate a little bit more on that kind of how you're designing your phase threes and allowing for flexibility of the patient maybe you're dealing with any sort of side effects
Surprised to see the performance, there was a little bit of sequential decline. So maybe you can just comment on the pricing and sort of market share dynamics
great data that you shared at ESMO. The commercial uptake for the quarter at least was a little bit less than we thought
the level of commitment you have there even if there is an impact from the tariff side, you still feel comfortable in being able to maintain and grow that
do you still see that business being relatively stable? This year relative to last year? Or has that changed from what your expectation
Just curious if you can comment on what you've seen so far gives you comfort in moving up for when we might see the data publicly
your broader views on the heart failure rate opportunity for that product